NCT03192969 is a Phase 3 clinical trial of Abatacept in Giant Cell Arteritis, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03192969?

NCT03192969 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03192969?

Interventions in NCT03192969: Abatacept, Placebo, Glucocorticoid Treatment.

What condition does NCT03192969 study?

NCT03192969 studies Giant Cell Arteritis.

Is NCT03192969 still recruiting?

NCT03192969 is currently withdrawn. Last updated 12 July 2017.

Last reviewed 2017-07-12 · How we verify

NCT03192969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Withdrawn Phase 3 Last updated 12 July 2017

What this trial tests

Phase 3 trial testing Abatacept in Giant Cell Arteritis. Withdrawn.

Timeline

15 July 2017

Primary endpoint
7 June 2020

23 November 2021

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	15 July 2017
Primary completion	7 June 2020
Estimated completion	23 November 2021
Sites	99 locations across Italy, Ireland, Poland, Denmark, Netherlands, Belgium, Sweden, Estonia

Drugs / interventions tested

Abatacept (abatacept) — full drug profile →
Placebo
Glucocorticoid Treatment — full drug profile →

Conditions studied

Giant Cell Arteritis — all drugs for Giant Cell Arteritis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

50 and older, any sex, with Giant Cell Arteritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment of Giant Cell Arteritis (GCA).
Régent A, Mouthon L. · · 2022 · cited 10× · PMID 35407411 · DOI 10.3390/jcm11071799
Soluble Co-Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case-Control Study.
Hysa E, Camellino D, Dejaco C, Bauckneht M, et al · · 2025 · cited 3× · PMID 40344345 · DOI 10.1002/acr2.70045

Verify or expand the search:

Other trials of Abatacept

Trials testing the same drug.

NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06929039 — Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity St · Phase 1 · completed
NCT06008808 — Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S · Phase 1 · recruiting
NCT03929601 — Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes · Phase 2 · active not recruiting

Other recruiting trials for Giant Cell Arteritis

Currently open trials in the same condition.

NCT07084480 — Giant Cell Arteritis - Ways to Precision Medicine · recruiting
NCT06894602 — Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis · recruiting
NCT05935709 — DANIsh VASculitis Database (DANIVAS) · recruiting
NCT06460142 — Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic · recruiting
NCT06011512 — Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03192969 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 12 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03192969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing